The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Identifieur interne : 000178 ( Main/Exploration ); précédent : 000177; suivant : 000179The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
Auteurs : Marzia Del Re [Italie] ; Stefano Fogli [Italie] ; Lisa Derosa [France] ; Francesco Massari [Italie] ; Paul De Souza [Australie] ; Stefania Crucitta [Italie] ; Sergio Bracarda [Italie] ; Daniele Santini [Italie] ; Romano Danesi [Italie]Source :
- Cancer treatment reviews [ 1532-1967 ] ; 2017.
Descripteurs français
- KwdFr :
- 3-Phényl-2-thiohydantoïne (analogues et dérivés), 3-Phényl-2-thiohydantoïne (métabolisme), 3-Phényl-2-thiohydantoïne (pharmacologie), Acétate d'abiratérone (métabolisme), Acétate d'abiratérone (pharmacologie), Antinéoplasiques (pharmacologie), Cytochrome P-450 enzyme system (), Humains, Interactions médicamenteuses, Mâle, Polypharmacie, Prednisone (pharmacologie), Tumeurs de la prostate (traitement médicamenteux).
- MESH :
- analogues et dérivés : 3-Phényl-2-thiohydantoïne.
- métabolisme : 3-Phényl-2-thiohydantoïne, Acétate d'abiratérone.
- pharmacologie : 3-Phényl-2-thiohydantoïne, Acétate d'abiratérone, Antinéoplasiques, Prednisone.
- traitement médicamenteux : Tumeurs de la prostate.
- Cytochrome P-450 enzyme system, Humains, Interactions médicamenteuses, Mâle, Polypharmacie.
English descriptors
- KwdEn :
- Abiraterone Acetate (metabolism), Abiraterone Acetate (pharmacology), Antineoplastic Agents (pharmacology), Cytochrome P-450 Enzyme System (drug effects), Drug Interactions, Humans, Male, Phenylthiohydantoin (analogs & derivatives), Phenylthiohydantoin (metabolism), Phenylthiohydantoin (pharmacology), Polypharmacy, Prednisone (pharmacology), Prostatic Neoplasms (drug therapy).
- MESH :
- chemical , analogs & derivatives : Phenylthiohydantoin.
- chemical , drug effects : Cytochrome P-450 Enzyme System.
- chemical , metabolism : Abiraterone Acetate, Phenylthiohydantoin.
- chemical , pharmacology : Abiraterone Acetate, Antineoplastic Agents, Phenylthiohydantoin, Prednisone.
- drug therapy : Prostatic Neoplasms.
- Drug Interactions, Humans, Male, Polypharmacy.
Abstract
Elderly patients with cancer may have comorbidities, each requiring additional pharmacologic treatment. Therefore, the occurrence of pharmacokinetic (PK) and pharmacodynamic (PD) interactions is very likely, and the risk of adverse reactions (ADRs), due to the narrow therapeutic window of anticancer drugs, is increased. Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications. Therefore, abiraterone may increase plasma levels of CYP2D6 substrates, including amitriptyline, oxycodone and risperidone, as well as of CYP2C8 substrates including amiodarone and carbamazepine. Since enzalutamide is extensively metabolized by CYP2C8, its plasma levels are likely to be raised if coadministered with strong CYP2C8 inhibitors such as gemfibrozil or pioglitazone. Inducers of CYP2C8 (i.e., rifampin) may reduce the effectiveness of enzalutamide and hence should be avoided. Enzalutamide may decrease plasma levels of CYP3A4, 2C9 and 2C19 substrates including disopiramide, quetiapine, quinidine and warfarin. Growing awareness of the importance of DDIs in cancer patients is now reflected in the variety of web-based sources offering information and guidance. However, the evaluation of the clinical relevance of DDIs is the result of a comprehensive evaluation of many factors, including therapeutic index, amplitude of therapeutic range and presence of comorbidities, requiring a specific expertise in clinical pharmacology.
DOI: 10.1016/j.ctrv.2017.03.001
PubMed: 28340451
Affiliations:
- Australie, France, Italie
- Latium, Nouvelle-Galles du Sud, Toscane
- Pise, Rome, Sydney
- Université de Pise
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D75
- to stream PubMed, to step Curation: 000D72
- to stream PubMed, to step Checkpoint: 000D72
- to stream Ncbi, to step Merge: 004528
- to stream Ncbi, to step Curation: 004528
- to stream Ncbi, to step Checkpoint: 004528
- to stream Main, to step Merge: 000173
- to stream Main, to step Curation: 000178
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.</title><author><name sortKey="Del Re, Marzia" sort="Del Re, Marzia" uniqKey="Del Re M" first="Marzia" last="Del Re">Marzia Del Re</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical and Experimental Medicine, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Fogli, Stefano" sort="Fogli, Stefano" uniqKey="Fogli S" first="Stefano" last="Fogli">Stefano Fogli</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, University of Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmacy, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Derosa, Lisa" sort="Derosa, Lisa" uniqKey="Derosa L" first="Lisa" last="Derosa">Lisa Derosa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Gustave Roussy Institute, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Oncology, Gustave Roussy Institute, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Massari, Francesco" sort="Massari, Francesco" uniqKey="Massari F" first="Francesco" last="Massari">Francesco Massari</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology Unit, Policlinico S. Orsola-Malpighi, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, University of Western Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, University of Western Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Crucitta, Stefania" sort="Crucitta, Stefania" uniqKey="Crucitta S" first="Stefania" last="Crucitta">Stefania Crucitta</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical and Experimental Medicine, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Bracarda, Sergio" sort="Bracarda, Sergio" uniqKey="Bracarda S" first="Sergio" last="Bracarda">Sergio Bracarda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Azienda USL Toscana Sud Est, Arezzo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Oncology, Azienda USL Toscana Sud Est, Arezzo</wicri:regionArea><wicri:noRegion>Arezzo</wicri:noRegion></affiliation></author><author><name sortKey="Santini, Daniele" sort="Santini, Daniele" uniqKey="Santini D" first="Daniele" last="Santini">Daniele Santini</name><affiliation wicri:level="3"><nlm:affiliation>Oncology Unit, Campus Bio-Medico University Hospital, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Oncology Unit, Campus Bio-Medico University Hospital, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Danesi, Romano" sort="Danesi, Romano" uniqKey="Danesi R" first="Romano" last="Danesi">Romano Danesi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: romano.danesi@unipi.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical and Experimental Medicine, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28340451</idno><idno type="pmid">28340451</idno><idno type="doi">10.1016/j.ctrv.2017.03.001</idno><idno type="wicri:Area/PubMed/Corpus">000D75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D75</idno><idno type="wicri:Area/PubMed/Curation">000D72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D72</idno><idno type="wicri:Area/PubMed/Checkpoint">000D72</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D72</idno><idno type="wicri:Area/Ncbi/Merge">004528</idno><idno type="wicri:Area/Ncbi/Curation">004528</idno><idno type="wicri:Area/Ncbi/Checkpoint">004528</idno><idno type="wicri:Area/Main/Merge">000173</idno><idno type="wicri:Area/Main/Curation">000178</idno><idno type="wicri:Area/Main/Exploration">000178</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.</title><author><name sortKey="Del Re, Marzia" sort="Del Re, Marzia" uniqKey="Del Re M" first="Marzia" last="Del Re">Marzia Del Re</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical and Experimental Medicine, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Fogli, Stefano" sort="Fogli, Stefano" uniqKey="Fogli S" first="Stefano" last="Fogli">Stefano Fogli</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacy, University of Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Pharmacy, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Derosa, Lisa" sort="Derosa, Lisa" uniqKey="Derosa L" first="Lisa" last="Derosa">Lisa Derosa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Gustave Roussy Institute, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Oncology, Gustave Roussy Institute, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Massari, Francesco" sort="Massari, Francesco" uniqKey="Massari F" first="Francesco" last="Massari">Francesco Massari</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology Unit, Policlinico S. Orsola-Malpighi, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, University of Western Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, University of Western Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Crucitta, Stefania" sort="Crucitta, Stefania" uniqKey="Crucitta S" first="Stefania" last="Crucitta">Stefania Crucitta</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical and Experimental Medicine, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Bracarda, Sergio" sort="Bracarda, Sergio" uniqKey="Bracarda S" first="Sergio" last="Bracarda">Sergio Bracarda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Azienda USL Toscana Sud Est, Arezzo, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Oncology, Azienda USL Toscana Sud Est, Arezzo</wicri:regionArea><wicri:noRegion>Arezzo</wicri:noRegion></affiliation></author><author><name sortKey="Santini, Daniele" sort="Santini, Daniele" uniqKey="Santini D" first="Daniele" last="Santini">Daniele Santini</name><affiliation wicri:level="3"><nlm:affiliation>Oncology Unit, Campus Bio-Medico University Hospital, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Oncology Unit, Campus Bio-Medico University Hospital, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Danesi, Romano" sort="Danesi, Romano" uniqKey="Danesi R" first="Romano" last="Danesi">Romano Danesi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: romano.danesi@unipi.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical and Experimental Medicine, University of Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region type="region" nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author></analytic><series><title level="j">Cancer treatment reviews</title><idno type="eISSN">1532-1967</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abiraterone Acetate (metabolism)</term><term>Abiraterone Acetate (pharmacology)</term><term>Antineoplastic Agents (pharmacology)</term><term>Cytochrome P-450 Enzyme System (drug effects)</term><term>Drug Interactions</term><term>Humans</term><term>Male</term><term>Phenylthiohydantoin (analogs & derivatives)</term><term>Phenylthiohydantoin (metabolism)</term><term>Phenylthiohydantoin (pharmacology)</term><term>Polypharmacy</term><term>Prednisone (pharmacology)</term><term>Prostatic Neoplasms (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>3-Phényl-2-thiohydantoïne (analogues et dérivés)</term><term>3-Phényl-2-thiohydantoïne (métabolisme)</term><term>3-Phényl-2-thiohydantoïne (pharmacologie)</term><term>Acétate d'abiratérone (métabolisme)</term><term>Acétate d'abiratérone (pharmacologie)</term><term>Antinéoplasiques (pharmacologie)</term><term>Cytochrome P-450 enzyme system ()</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Mâle</term><term>Polypharmacie</term><term>Prednisone (pharmacologie)</term><term>Tumeurs de la prostate (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Phenylthiohydantoin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Cytochrome P-450 Enzyme System</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Abiraterone Acetate</term><term>Phenylthiohydantoin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Abiraterone Acetate</term><term>Antineoplastic Agents</term><term>Phenylthiohydantoin</term><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>3-Phényl-2-thiohydantoïne</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>3-Phényl-2-thiohydantoïne</term><term>Acétate d'abiratérone</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>3-Phényl-2-thiohydantoïne</term><term>Acétate d'abiratérone</term><term>Antinéoplasiques</term><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Interactions</term><term>Humans</term><term>Male</term><term>Polypharmacy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cytochrome P-450 enzyme system</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Mâle</term><term>Polypharmacie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Elderly patients with cancer may have comorbidities, each requiring additional pharmacologic treatment. Therefore, the occurrence of pharmacokinetic (PK) and pharmacodynamic (PD) interactions is very likely, and the risk of adverse reactions (ADRs), due to the narrow therapeutic window of anticancer drugs, is increased. Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications. Therefore, abiraterone may increase plasma levels of CYP2D6 substrates, including amitriptyline, oxycodone and risperidone, as well as of CYP2C8 substrates including amiodarone and carbamazepine. Since enzalutamide is extensively metabolized by CYP2C8, its plasma levels are likely to be raised if coadministered with strong CYP2C8 inhibitors such as gemfibrozil or pioglitazone. Inducers of CYP2C8 (i.e., rifampin) may reduce the effectiveness of enzalutamide and hence should be avoided. Enzalutamide may decrease plasma levels of CYP3A4, 2C9 and 2C19 substrates including disopiramide, quetiapine, quinidine and warfarin. Growing awareness of the importance of DDIs in cancer patients is now reflected in the variety of web-based sources offering information and guidance. However, the evaluation of the clinical relevance of DDIs is the result of a comprehensive evaluation of many factors, including therapeutic index, amplitude of therapeutic range and presence of comorbidities, requiring a specific expertise in clinical pharmacology.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Italie</li></country><region><li>Latium</li><li>Nouvelle-Galles du Sud</li><li>Toscane</li></region><settlement><li>Pise</li><li>Rome</li><li>Sydney</li></settlement><orgName><li>Université de Pise</li></orgName></list><tree><country name="Italie"><region name="Toscane"><name sortKey="Del Re, Marzia" sort="Del Re, Marzia" uniqKey="Del Re M" first="Marzia" last="Del Re">Marzia Del Re</name></region><name sortKey="Bracarda, Sergio" sort="Bracarda, Sergio" uniqKey="Bracarda S" first="Sergio" last="Bracarda">Sergio Bracarda</name><name sortKey="Crucitta, Stefania" sort="Crucitta, Stefania" uniqKey="Crucitta S" first="Stefania" last="Crucitta">Stefania Crucitta</name><name sortKey="Danesi, Romano" sort="Danesi, Romano" uniqKey="Danesi R" first="Romano" last="Danesi">Romano Danesi</name><name sortKey="Fogli, Stefano" sort="Fogli, Stefano" uniqKey="Fogli S" first="Stefano" last="Fogli">Stefano Fogli</name><name sortKey="Massari, Francesco" sort="Massari, Francesco" uniqKey="Massari F" first="Francesco" last="Massari">Francesco Massari</name><name sortKey="Santini, Daniele" sort="Santini, Daniele" uniqKey="Santini D" first="Daniele" last="Santini">Daniele Santini</name></country><country name="France"><noRegion><name sortKey="Derosa, Lisa" sort="Derosa, Lisa" uniqKey="Derosa L" first="Lisa" last="Derosa">Lisa Derosa</name></noRegion></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000178 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000178 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28340451
|texte= The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28340451" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |